314 related articles for article (PubMed ID: 27063754)
1. Risk of systemic allergic reactions to allergen immunotherapy in a pediatric allergy clinic in Turkey.
Bahceci Erdem S; Nacaroglu HT; Karaman S; Unsal Karkıner CS; Gunay I; Dogan D; Asilsoy S; Altınoz S; Can D
Int J Pediatr Otorhinolaryngol; 2016 May; 84():55-60. PubMed ID: 27063754
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of adverse reactions induced by subcutaneous immunotherapy against dust mite allergy in 234 cases with allergic rhinitis and asthma].
Li MR; Wang XN; Jiang HD; Wang QY; Li YC; Lin J; Jin K; Zhang HL; Li CC
Zhonghua Er Ke Za Zhi; 2012 Oct; 50(10):726-31. PubMed ID: 23302557
[TBL] [Abstract][Full Text] [Related]
3. Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkey.
Kartal O; Gulec M; Caliskaner Z; Musabak U; Sener O
Immunopharmacol Immunotoxicol; 2015 Jun; 37(3):280-6. PubMed ID: 25858053
[TBL] [Abstract][Full Text] [Related]
4. [Observation and analysis of systemic reactions to house dust mite subcutaneous immunotherapy in 362 patients with allergic rhinitis].
Xue JR; Ma J; Qiu CY; Hu ZB; Jiang X; Pan M; Lu MP; Cheng L
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 May; 55(5):445-451. PubMed ID: 32842357
[No Abstract] [Full Text] [Related]
5. Effectiveness and adverse reactions to subcutaneous immunotherapy in children with allergic rhinitis/asthma.
Duman Senol H; Topyildiz E; Ekici B; Gulen F; Demir E
Int J Pediatr Otorhinolaryngol; 2022 Nov; 162():111292. PubMed ID: 36007303
[TBL] [Abstract][Full Text] [Related]
6. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
[TBL] [Abstract][Full Text] [Related]
7. The safety profile of subcutaneous allergen immunotherapy in children with asthma in Hangzhou, East China.
Liu JL; Ning WX; Li SX; Xu YC; Wu L; Wang YS; Xu XF; Jiang Y; Sheng YJ; Zhou YL; Wang JH; Tang LF; Chen ZM
Allergol Immunopathol (Madr); 2017; 45(6):541-548. PubMed ID: 28629672
[TBL] [Abstract][Full Text] [Related]
8. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions.
Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
J Allergy Clin Immunol Pract; 2014; 2(2):161-7. PubMed ID: 24607043
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Pediatric and Adult Systemic Reactions to Subcutaneous Immunotherapy.
Lim CE; Sison CP; Ponda P
J Allergy Clin Immunol Pract; 2017; 5(5):1241-1247.e2. PubMed ID: 28341172
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008-2013).
Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
Ann Allergy Asthma Immunol; 2016 Apr; 116(4):354-359.e2. PubMed ID: 26948485
[TBL] [Abstract][Full Text] [Related]
11. The safety of allergen immunotherapy (IT) in Turkey.
Dursun AB; Sin BA; Oner F; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(2):123-8. PubMed ID: 16689186
[TBL] [Abstract][Full Text] [Related]
12. Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases.
Yang Y; Ma D; Huang N; Li W; Jiang Q; Wang Y; Wang X; Yang L; Zhu R
Ital J Pediatr; 2021 Apr; 47(1):101. PubMed ID: 33892756
[TBL] [Abstract][Full Text] [Related]
13. Systemic reactions to subcutaneous allergen immunotherapy and the response to epinephrine.
Phillips JF; Lockey RF; Fox RW; Ledford DK; Glaum MC
Allergy Asthma Proc; 2011; 32(4):288-94. PubMed ID: 21781404
[TBL] [Abstract][Full Text] [Related]
14. The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A paediatric assessment.
Rodríguez Del Río P; Vidal C; Just J; Tabar AI; Sanchez-Machin I; Eberle P; Borja J; Bubel P; Pfaar O; Demoly P; Calderón MA
Pediatr Allergy Immunol; 2017 Feb; 28(1):60-70. PubMed ID: 27637414
[TBL] [Abstract][Full Text] [Related]
15. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System.
Cox L; Larenas-Linnemann D; Lockey RF; Passalacqua G
J Allergy Clin Immunol; 2010 Mar; 125(3):569-74, 574.e1-574.e7. PubMed ID: 20144472
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for fatal and nonfatal reactions to immunotherapy (2008-2018): postinjection monitoring and severe asthma.
Epstein TG; Murphy-Berendts K; Liss GM; Bernstein DI
Ann Allergy Asthma Immunol; 2021 Jul; 127(1):64-69.e1. PubMed ID: 33753219
[TBL] [Abstract][Full Text] [Related]
17. Detection of risk factors for systemic adverse reactions to SCIT with natural depot allergen extracts: a retrospective study.
Asero R
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):211-7. PubMed ID: 26549339
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of systemic reactions to subcutaneous immunotherapy with airborne allergens and classification according to WAO 2010.
Santos N; Pereira AM; Silva R; Torres da Costa J; Plácido JL
Allergol Immunopathol (Madr); 2015; 43(1):25-31. PubMed ID: 24661594
[TBL] [Abstract][Full Text] [Related]
19. Adverse reactions to subcutaneous immunotherapy in patients with allergic rhinitis, a real-world study.
Zhang W; Deng Y; Tong H; Xiang R; Chen S; Kong Y; Tao Z; Xu Y
Eur Arch Otorhinolaryngol; 2021 Nov; 278(11):4353-4360. PubMed ID: 33713192
[TBL] [Abstract][Full Text] [Related]
20. A 10-year experience of a novel and safe modified environmental rush immunotherapy protocol.
Fajt ML; Rosenberg SL; Yecies E; Traister RS; Petrov AA
Allergy Asthma Proc; 2017 Jul; 38(4):309-316. PubMed ID: 28668111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
